Schott Doubles Production Capacity for Polymer Syringes
Schott installed a new line in its St. Gallen, Switzerland facility to manufacture small-size (1 to 10 mL), ready-to-fill syringes made of cyclic olefin copolymer (COC), the company noted in a press release. This expansion doubles Schott’s production capacity for COC syringes.
COC is an inert material that is compatible with a broad range of drugs. Schott says its syringes have excellent barrier properties and glass-like transparency and are break-resistant and lightweight. The syringes are manufactured in cleanrooms using a fully automated process from injection molding to the final packaging. The syringes are sterilized and are ready for aseptic-filling operations.
Current Issue
Fill/Finish Capacity Use for Biologics
There are significant differences between small molecules and biologics fill/finish capacity.
Drug Breakthroughs, with Some Reservations
New designations lead to faster drug approvals, but there is more work to be done.
Outsourcing
Baxter BioPharma Solutions Joins PBOA
Nelson Patterson has been elected to Pharma & Biopharma Outsourcing Association board.
Fill/Finish Capacity Use for Biologics
There are significant differences between small molecules and biologics fill/finish capacity.
New England CRO/CMO Council Debuts
New organization offers support to contract research organizations and contract manufacturing organizations in the New England area.
Year in Review: Key Outsourcing Trends
Outsourcing is taking on a greater role in the biopharmaceutical manufacturing industry.
Standards/Regulations
EMA Sets Elemental Impurities Implementation Dates
New drugs submitted for approval in Europe have 18 months to comply with new elemental impurities guidelines.
Compounding Committee Meets to Discuss Drugs Approved for Compounding
FDA’s Pharmacy Compounding Advisory Committee will meet in February to discuss the list of bulk drug substances that may or may not be compounded.
The Quest Continues for Quality Metrics
FDA aims is to collect data regularly from manufacturers that will indicate the ability of a firm and its facilities to produce high-quality therapies on a continual, error-free basis.
Webcasts
